Hawaii · 2026 Regular Session
Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 12/31/2050. (SD1)
Carried over to 2026 Regular Session. (2025-12-08)